Company Profile
Sagimet Biosciences Stock Price, News & Catalysts
- Ticker:
- SGMT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
10.43 USD (-1.14%)
Close
Last updated: August 17, 2026
419M USD
Market cap
Why the stock is moving
The latest monitored company update is “Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Metabolic Pathway Therapeutics
Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production.
Denifanstat
Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.
Dermatology Focus
Sagimet is prioritizing moderate-to-severe acne, where reduced sebaceous lipid synthesis may address an upstream disease mechanism.
Future catalysts
- A U.S. Phase 3 study of denifanstat in moderate-to-severe acne is planned to begin in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sagimet Biosciences (SGMT)?
Sagimet Biosciences (SGMT) most recently closed at 10.43 USD, a -1.14% move versus the previous session.
What is the market cap of Sagimet Biosciences (SGMT)?
Sagimet Biosciences currently has a market capitalization of 419M USD on BioPharmSignal.
What does Sagimet Biosciences do?
Metabolic Pathway Therapeutics Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production. Denifanstat Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology. Dermatology Focus Sagimet is prioritizing moderate-to-severe...
On which exchange is SGMT stock listed?
Sagimet Biosciences (SGMT) is associated with NASDAQ, United States, Biopharma.
What is denifanstat?
Phase 3 study of denifanstat in moderate-to-severe acne is planned to begin in the second half of 2026.
Which conditions is Sagimet Biosciences targeting with denifanstat?
Sagimet Biosciences is associated with metabolic disease, dermatology based on its company overview and current catalyst commentary.
How does Sagimet Biosciences describe recent progress with denifanstat?
Phase 3 study of denifanstat in moderate-to-severe acne is planned to begin in the second half of 2026.
What is Metabolic?
Metabolic Pathway Therapeutics Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production.